Immunotherapy demonstrates long-term success in treating lymphoma

Targeted immunotherapy has been an attractive new therapeutic area for a number of cancers because it has the potential to destroy tumour cells without damaging surrounding normal tissue. New study results demonstrate high success rates using specialised white blood cells to prevent or treat lymphoma associated with the Epstein-Barr virus (EBV-lymphoma) in patients who have received a hematopoietic stem cell transplant (HSCT). This study was pre-published online today in Blood, the official journal of the American Society of Hematology...

Read the whole article on

More from